Humana Stock Near Crucial Support – Buy Signal?
Humana (HUM) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($197.53 – $218.33), levels from which it has bounced meaningfully before. In the last 10 years, Humana stock received buying interest at this level 6 times and subsequently went on to generate 39.6% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 1/12/2018 | 32.7% | 299 |
| 6/21/2019 | 13.1% | 53 |
| 10/11/2019 | 43.0% | 125 |
| 3/25/2020 | 113.2% | 953 |
| 7/30/2025 | 19.3% | 36 |
| 10/2/2025 | 16.1% | 6 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for HUM?
MA rate shock makes near-term rebound unlikely.
Humana faces severe near-term headwinds. The proposed 0.09% Medicare Advantage payment increase for 2027, announced January 27, 2026, cratered shares over 20%, far below the expected 4-6% rise. This regulatory shift significantly pressures margins in its core business. While analysts previously held median price targets around $287-$290, recent revisions reflect this new reality. Q4 2025 earnings, due February 11, and 2026 guidance will be crucial, but the MA rate news casts a long shadow. Anticipated 2025 MA membership decline further complicates growth. Industry-wide medical cost trends of 8-9% in 2026 add pressure, despite some long-term margin recovery hopes.
- Get Paid 9.0% to Buy INTU at a 30% Discount – Here’s How
- What Could Rocket NVIDIA Stock to New Heights
- 3 Key Risks That Could Drag Down Lam Research Stock
- Cash Machine Trading Cheap – Surgery Partners Stock Set to Run?
- What’s Next For Corning Stock?
- Abbott Laboratories Stock: Join the Rally at a 19% Discount
How Do HUM Financials Look Right Now?
- Revenue Growth: 9.9% LTM and 11.4% last 3-year average.
- Cash Generation: Nearly 1.2% free cash flow margin and 0.0% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for HUM was 9.9%.
- Valuation: HUM stock trades at a PE multiple of 19.4
| HUM | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Managed Health Care | – |
| PE Ratio | 19.4 | 24.3 |
|
|
||
| LTM* Revenue Growth | 9.9% | 6.4% |
| 3Y Average Annual Revenue Growth | 11.4% | 5.6% |
| Min Annual Revenue Growth Last 3Y | 9.9% | 0.2% |
|
|
||
| LTM* Operating Margin | � | 18.8% |
| 3Y Average Operating Margin | � | 18.4% |
| LTM* Free Cash Flow Margin | 1.2% | 13.5% |
*LTM: Last Twelve Months | For more details on HUM fundamentals, read Buy or Sell HUM Stock.
And What If The Support Breaks?
HUM isn’t immune to big drops, even with strong fundamentals. It fell about 77% during the Dot-Com bubble and hit nearly 78% in the Global Financial Crisis. More recently, the 2018 correction took it down 34%, and the Covid pandemic wiped out around 44%. The Inflation Shock caused a smaller dip near 24%. So, while quality counts, HUM still faces major selloffs when markets turn sour.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read HUM Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about HUM stock? Consider the portfolio approach.
Portfolios Over Individual Stock Picks
Stocks can jump or crash but long term success comes from staying invested. The right portfolio helps you ride gains and cushion single stock drops
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.